EVOLVING LANDSCAPE OF INFLAMMATORY BOWEL DISEASE IN G20 NATIONS (1990-2019): A COMPREHENSIVE GLOBAL ASSESSMENT

Rahul Patel,Krishna Sajeev,Vani Sojitra,Krina Manojbhai Patel,Pranathi Royal Naradasu,Sneh Patel,Hardik Dineshbhai Desai

DOI: https://doi.org/10.1093/ibd/izae020.069

2024-01-25

Inflammatory Bowel Diseases

Abstract:Abstract BACKGROUND As pivotal players in the global economy, the G20 countries not only lead in economic dynamics but also in health challenges. Recent data reveals an escalating burden of Inflammatory Bowel Disease (IBD) in these nations. Understanding this trend is crucial to frame healthcare strategies and ensure the well-being of a significant portion of the global population. METHOD We employed data on IBD prevalence, incidence, mortality, and DALYs for G20 countries from the Global Burden of Disease (GBD) 2019 study. Using standardized statistical techniques, we analyzed by age, sex, year and location across G20 countries, estimating incidence and prevalence with the DisMod-MR 2.1 tool and mortality through the Cause of Death Ensemble Model (CODEm). RESULTS From 1990 to 2019, IBD prevalence figures in the G20 nations escalated from 2,999,730 (95%UI: 2,625,581-3,416,963) to 4,254,467 (3,809,445-4,751,041), marking a 42% (38-46) surge in the Annual Percentage Change (APC). Meanwhile, the incidence rose by 30% (26-35), mortality by 72% (49-97), and DALYs by 27% (15-43). Among these nations, China witnessed a striking 314% increase in incidence, closely followed by South Korea at 288%. Death rates were most pronounced in European Union members, with Portugal at the helm (441%), trailed by Italy (433%) and Germany (418%). Germany also led in DALYs growth with a 289% APC. Examining Age-standardized mortality rates, Germany again topped the list with a 244% increase, shadowed by Italy (186%) and the United States (147%). Over the past three decades, older populations demonstrated a rising IBD burden. In gender comparisons, males experienced a more significant incidence increase (32% vs. females at 28%) and DALYs (30% vs. females at 24%). Conversely, females had a steeper death rate growth, 77% as opposed to males at 67%. CONCLUSION In 2019, IBD was responsible for 2.02% of digestive disease-related deaths and 2.30% of associated disabilities in the G20 nations. The stark rise in IBD prevalence, especially in countries like China, South Korea, and European Union members, emphasizes a pressing need for targeted clinical approaches and proactive health policies to mitigate this escalating burden. Age-standardized rate (per 100,000 person years) of Inflammatory Bowel Disease in G20 Countries, 2019. A: ASIR, B: ASMR, C:ASDALR.

gastroenterology & hepatology

What problem does this paper attempt to address?

The problems this paper attempts to address are:

1. **"Trends in Inflammatory Bowel Disease (IBD) in G20 Countries (1990-2019): A Comprehensive Global Assessment"**:
- Research Background: G20 countries are not only significant participants in the global economy but also face increasing health challenges, particularly the burden of Inflammatory Bowel Disease (IBD). Understanding this trend is crucial for developing effective healthcare strategies and ensuring the health of the global population.
- Main Issue: This study aims to analyze the trends in prevalence, incidence, mortality, and Disability-Adjusted Life Years (DALYs) of IBD in G20 countries from 1990 to 2019, and to explore the differences in these changes across different ages, genders, and regions.

2. **"Exploring Factors Affecting Serological Response to SARS-CoV-2 Vaccine in Patients with Inflammatory Bowel Disease: An Interactive Visualization Approach with Multidimensional Data"**:
- Research Background: The response to the SARS-CoV-2 vaccine may be lower in elderly individuals (65 years and older) and IBD patients receiving anti-TNF therapy. In the COVID-19 era, rapidly communicating evolving health information, especially to high-risk groups such as the elderly and immunocompromised individuals, is a challenge.
- Main Issue: This study aims to explore various factors affecting the serological response to the SARS-CoV-2 vaccine in IBD patients and to develop an interactive visualization approach with multidimensional data to better communicate this information.